Clinical Trial Update: Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating the antidepressant effects of 2R,6R-hydroxynorketamine (HNK) as a glutamate-release enhancer for treatment-resistant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Treatment-resistant Depression

Drugs mentioned

• (2R,6R)-Hydroxynorketamine (Hydroxynorketamine)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Suicide, Depressive Disorder, Treatment-Resistant | Phase 2 | Status: RECRUITING